Jason Gaglia M.D., M.M.Sc.

Dr. Gaglia is a physician scientist; many of his research projects are inspired by questions raised in the clinic, with Type 1 diabetes being a major focus. He is developing clinically applicable techniques to monitor insulitis (the destructive process that leads to Type 1 diabetes) and peripheral markers of diabetes related autoimmunity. In collaboration with other investigators, Dr. Gaglia is applying these techniques to learn more about the underlying processes that lead to Type 1 diabetes, as well as developing novel treatment strategies for this disease.

Clinical trials in Type 1 diabetes:

Dr. Gaglia's clinical trials group participates in several Type 1 diabetes clinical trials consortia including Type 1 Diabetes TrialNet and the Immune Tolerance Network.  

Monitoring autoimmunity in diabetes:

Currently, islet-antigen-targeted autoantibody tests are used as a peripheral marker of the autoimmunity that leads to Type 1 diabetes. However, these autoantibodies are immunologically distant from the destructive processes that cause diabetes. Dr. Gaglia's lab is developing new peripheral assays of autoimmunity in diabetes.

Gaglia

Office Phone Number: 1-617-309-4030

jason(dot)gaglia(at)joslin(dot)harvard(dot)edu